Sequana Medical Investor Presentation October 2021

Sequana Medical presents innovations in treating diuretic-resistant fluid overload across liver disease, malignant ascites, and heart failure indications. The presentation outlines the company's alfapump® system and DSR® therapy platforms, which address critical unmet needs in fluid management. Regulatory statuses and clinical development programs, including the POSEIDON study, are detailed.